Literature DB >> 4597704

Phosphorylation of lividomycin by Escherichia coli carrying an R factor.

M Yamaguchi, T Koshi, F Kobayashi, S Mitsuhashi.   

Abstract

A lividomycin-phosphorylating enzyme from a lividomycin-resistant strain of Escherichia coli carrying an R factor was partially purified by fractionation with ammonium sulfate and Sephadex G-100 column chromatography. The enzyme inactivated, in the presence of adenosine triphosphate and Mg(2+), several antibiotics having a d-ribose moiety linked to 2-deoxystreptamine, i.e., lividomycin A and B, neomycin, paromomycin, and vistamycin, but did not inactivate the kanamycins, streptomycin, or the gentamicin C components. Chemical studies of the inactivated product suggested that the phosphorylated site of the inactivated lividomycin was the hydroxyl group of the d-ribose moiety.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4597704      PMCID: PMC444281          DOI: 10.1128/AAC.2.3.142

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Adenylylstreptomycin, a product of streptomycin inactivated by E. coli carrying R factor.

Authors:  H Umezawa; S Takasawa; M Okanishi; R Utahara
Journal:  J Antibiot (Tokyo)       Date:  1968-01       Impact factor: 2.649

2.  Chloramphenicol-, dihydrostreptomycin-, and kanamycin-inactivating enzymes from multiple drug-resistant Escherichia coli carrying episome 'R'.

Authors:  S Okamoto; Y Suzuki
Journal:  Nature       Date:  1965-12-25       Impact factor: 49.962

3.  Isolation of kanamycin and paromamine inactivated by E. coli carrying R factor.

Authors:  S Kondo; M Okanishi; R Utahara; K Maeda; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1968-01       Impact factor: 2.649

4.  Aminoglycoside antibiotics: inactivation by phosphorylation in Escherichia coli carrying R factors.

Authors:  B Ozanne; R Benveniste; D Tipper; J Davies
Journal:  J Bacteriol       Date:  1969-11       Impact factor: 3.490

5.  Phosphorylation and inactivation of kanamycin by Pseudomonas aeruginosa.

Authors:  H Umezawa; O Doi; M Ogura; S Kondo; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1968-02       Impact factor: 2.649

6.  Inactivation and phosphorylation of kanamycin by drug-resistant Staphylococcus aureus.

Authors:  O Doi; M Miyamoto; N Tanaka; H Umezawa
Journal:  Appl Microbiol       Date:  1968-09

7.  Recent developments in the chemistry of gentamicin.

Authors:  D J Cooper; H M Marigliano; M D Yudis; T Traubel
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

8.  Resistance factor-mediated streptomycin resistance.

Authors:  J H Harwood; D H Smith
Journal:  J Bacteriol       Date:  1969-03       Impact factor: 3.490

9.  Inactivation of kanamycin, neomycin, and streptomycin by enzymes obtained in cells of Pseudomonas aeruginoa.

Authors:  O Doi; M Ogura; N Tanaka; H Umezawa
Journal:  Appl Microbiol       Date:  1968-09

10.  Antibacterial activity of lividomycin toward R factor-resistant strains of Escherichia coli.

Authors:  M Yamaguchi; F Kobayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

View more
  4 in total

Review 1.  Drug resistance plasmids.

Authors:  S Mitsuhashi
Journal:  Mol Cell Biochem       Date:  1979-08-15       Impact factor: 3.396

2.  Selective phosphorylation of the 5''-hydroxy group of ribostamycin by a new enzyme from Pseudomonas aeruginosa.

Authors:  M Kida; S Igarasi; T Okutani; T Asako; K Hiraga
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

3.  Phosphorylation of kanamycin, lividomycin A, amd butirosin B by Providencia stuartii.

Authors:  P B Marengo; M E Chenoweth; G D Overturf; J Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

4.  Lividomycin resistance in staphylococci by enzymatic phosphorylation.

Authors:  F Kobayashi; T Koshi; J Eda; Y Yoshimura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1973-07       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.